Effect of a neuraminidase inhibitor (oseltamivir) on mouse jump-down behavior via stimulation of dopamine receptors

Biomedical Research

Volumn 29, Issue 5, 2008, Pages 233-238

  Suzuki, Minoru ^a   Masuda, Yutaka ^a  

^a AKITA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO 5 HYDROXYTETRALIN; DOPAMINE 2 RECEPTOR; DOPAMINE 2 RECEPTOR STIMULATING AGENT; GLYCOLIPID; OSELTAMIVIR; SIALOGLYCOLIPID; UNCLASSIFIED DRUG; 2 (N PHENETHYL N PROPYL)AMINO 5 HYDROXYTETRALIN; 2-(N-PHENETHYL-N-PROPYL)AMINO-5-HYDROXYTETRALIN; DOPAMINE RECEPTOR STIMULATING AGENT; ENZYME INHIBITOR; PHENETHYLAMINE DERIVATIVE; SIALIDASE; SIALOGLYCOLIPIDS;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BEHAVIOR DISORDER; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG RESPONSE; DRUG SAFETY; JUMPING; LIPID BLOOD LEVEL; MALE; MOUSE; NONHUMAN; PROTEIN FUNCTION; SIALYLATION; ADOLESCENT; ADULT; ANIMAL; BLOOD; CHILD; DRUG ANTAGONISM; HUMAN; METABOLISM; MOTOR ACTIVITY;

MUS;

ADOLESCENT; ANIMALS; BEHAVIOR, ANIMAL; CHILD; DOPAMINE AGONISTS; ENZYME INHIBITORS; GLYCOLIPIDS; HUMANS; MALE; MICE; MOTOR ACTIVITY; NEURAMINIDASE; OSELTAMIVIR; PHENETHYLAMINES; RECEPTORS, DOPAMINE D2; YOUNG ADULT;

EID: 58149342104     PISSN: 03886107     EISSN: 1880313X     Source Type: Journal    
DOI: 10.2220/biomedres.29.233     Document Type: Article

References (26)

1. Becker CG, Artola A, Gerardy-Schahn R, Becker T, Welzl H and Schachner M (1996) The polysialic acid modification of the neural cell adhesion molecule is involved in spatial learning and hippocampal long-term potentiation. J Neurosci Res 45, 143-152.
2. Boyzo A, Ayala J, Gutiérrez R and Hernández-R J (2003) Neuraminidase activity in different regions of the seizing epileptic and non-epileptic brain. Brain Res 964, 211-217.
3. Chen WF, Chen JJ and Chen L (1995) Excitation of hypothalamic nucleus arcuatus neuron induced decrease of plasma sialic acid level in rats. Sheng Li Xue Bao 47, 597-600. (in Chinese)
4. Cooper NJ, Sutton AJ, Abrams KR, Wailoo A, Turner D and Nicholson KG (2003) Effectiveness of neuraminidase inhibitors in treatment and prevention of influenza A and B: systematic review and meta-analyses of randomised controlled trials. BMJ 326, 1235.
5. Crain SM and Shen KF (2004) Neuraminidase inhibitor, oseltamivir blocks GM1 ganglioside-regulated excitatory opioid receptor-mediated hyperalgesia, enhances opioid analgesia and attenuates tolerance in mice. Brain Res 995, 260-266.
6. Gendreau PL, Petitto JM, Gariepy JL and Lewis MH (1998) D2-like dopamine receptor mediation of social-emotional reactivity in a mouse model of anxiety: strain and experience effects. Neuropsychopharmacology 18, 210-221.
7. Hama R (2005) Discussion of the causal relationship between oseltamivir phosphate (Tamiflu), and sudden death and death from abnormal behavior. 37th Annual Meeting of the Japanese Society for Pediatric Infectious Diseases. November 2005.
8. Hama R (2006) Tamiflu causes abnormal behaviors at noon (after taking first time) of the first day. Part 1. The Informed Prescriber 21, 110-116. (in Japanese)
9. Hama R (2007) Oseltamivir's adverse reactions: fifty sudden deaths may be related to central suppression. BMJ 335, 59.
10. Hui KS and Roberts MB (1975) An improved implantation pellet for rapid induction of morphine dependence in mice. J Pharmacol 27, 569-573.
11. Izumi Y, Tokuda K, O'dell KA, Zorumski CF and Narahashi T (2007) Neuroexcitatory actions of Tamiflu and its carboxylate metabolite. Neurosci Lett 426, 54-58.
12. Japan issues Tamiflu warning after child deaths. Times March 21, 2007. http://www.timesonline.co.uk/tol/news/world/asia/ article1549260.ece.
13. Jefferson T, Demicheli V, Rivetti D, Jones M, Di Pietrantonj C and Rivetti A (2006) Antivirals for influenza in healthy adults: systematic review. Lancet 367, 303-313.
14. Li CY, Yu Q, Ye ZQ, Sun Y, He Q, Li XM, Thang W, Luo J, Gu X, Zheng X and Wei L (2007) A nonsynonymous SNP in human cytosolic sialidase in a small Asian population results in reduced enzyme activity: potential link with severe adverse reactions to oseltamivir. Cell Res 17, 357-362.
15. Masuda Y (2007) Sialic acid-rich glycolipid of schizophrenia sera. Akita J Med 34, 123-127.
16. Masuda Y, Sugawara J, Ohnuma S and Sugiyama T (2002) Humoral GalNAcα1-3GalNAc-lipid reactivity of humans in hypomanic state. Tohoku J Exp Med 197, 115-118.
17. Masuda Y, Suzuki M, Takemura T, Sugawara J, Guo N, Liu Y, Kawarada Y, Shimizu T and Sugiyama T (2003) Pharmacological mechanism in slip-down behavior of mice. Tohoku J Exp Med 201, 23-27.
18. Maxwell SR (2007) Tamiflu and neuropsychiatric disturbance in adolescents. BMJ 334, 1232-1233.
19. National Institute for Clinical Excellence. Amantadine, oseltamivir and zanamivir for the treatment of influenza (review of existing guidance No. 58). October 2007. http://guidance.nice.org.uk/ page.aspx?o=456310.
20. Okumura A, Kubota T, Kato T and Morishima T (2006) Oseltamivir and delirious behavior in children with influenza. Pediatr Infect Dis J 25, 572.
21. Radad K, Gille G, Moldzio R, Saito H and Rausch WD (2004) Ginsenosides Rb1 and Rg1 effects on mesencephalic dopaminergic cells stressed with glutamate. Brain Res 1021, 41-53.
22. Rodriguez JA, Piddini E, Hasegawa T, Miyagi T and Dotti CG (2001) Plasma membrane ganglioside sialidase regulates axonal growth and regeneration in hippocampal neurons in culture. J Neurosci 21, 8387-8395.
23. Satoh K, Nonaka R, Ogata A, Nakae D and Uehara S (2007) Effects of oseltamivir phosphate (Tamiflu) and its metabolite (GS4071) on monoamine neurotransmission in the rat brain. Biol Pharm Bull 30, 1816-1818.
24. Schauer R (2000) Achievements and challenges of sialic acid research. Glycoconj J 17, 485-499.
25. Seyrantepe V, Poupetova H, Froissart R, Zabot MT, Maire I and Pshezhetsky AV (2003) Molecular pathology of NEU1 gene in sialidosis. Hum Mutat 22, 343-352.
26. Traving C and Schauer R (1998) Structure, function and metabolism of sialic acids. Cell Mol Life Sci 54, 1330-1349.